Exploratory Evaluation of [11C]MPC6827

Summary

This is a phase 0 study that will enable an assessment of biodistribution and estimation of absorbed dose in humans based on data collected from five healthy volunteers, which is typically the minimum number required by the FDA for first-in-human studies to assess dosimetry of a new tracer. The evaluation of the brain imaging of thirty additional subjects in the 2nd part of the study will lead to a descriptive assessment of the targeting and pharmacokinetics of MPC6827 in the brain and between normal and diseased brain.

Timeline

Start

2021-01-08

Primary completion

2024-06-21

Completion

2024-06-21

Publications

• Zanderigo F, Laurell GL, Doubrovin M, Molotkov A, Ali A, Arevalo RF, Solingapuram Sai KK, Mann JJ, Mintz A. Imaging Microtubule Dynamics In Vivo in Human Brain: Optimal Quantification Based on a Test-Retest Study. J Nucl Med. 2026 Apr 1;67(4):644-650. doi: 10.2967/jnumed.125.271335.

Drugs

Indications